For patients with nonmetastatic prostate cancer, focal therapy use has remained uncommon across risk groups, and its use was defined as inappropriate in about half of recipients, according to a research letter published online Aug. 13 in the JAMA.

How each outlet headlined it

• Medical Xpress

  For patients with nonmetastatic prostate cancer, focal therapy use has remained uncommon across risk groups, and its use was defined as inappropriate in about half of recipients, according to a research letter published online Aug. 13 in the JAMA.
  
• The Washington Post left

  Column by Mikkael Sekeres, MD: With over 330,000 new cases estimated for 2026, prostate cancer accounts for almost one-third of all invasive cancers in men. Here's why regular prostate cancer screening is not recommended for all men: